女性健康治疗市场规模、份额和增长分析（按年龄、药物、分销管道、应用和地区）- 行业预测 2025-2032

预计 2023 年女性健康治疗市场规模将达到 137 亿美元，并从 2024 年的 144.5 亿美元增长到 2032 年的 221.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.5%。

全球女性健康治疗市场正在经历消费者偏好的变化，导致对健康零食，尤其是水果零食的需求增加。由于人们认为水果零食是一种方便又健康的零食替代品，该领域展现了弹性和稳定的成长。随着消费者的健康意识不断增强，低热量、不含人工添加物、由真正的水果製成的零嘴零食明显受到消费者的青睐。预计这种注重健康的趋势将对市场产生进一步影响。作为回应，水果零食产业的公司正在投资产品创新，推出有机、非基因改造和洁净标示的产品，同时也在探索新的口味和包装解决方案以吸引更多消费者。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

女性保健药物市场规模（按年龄和复合年增长率） (2025-2032)

• 市场概况
• 年龄 50 岁或以上
• 其他的

女性保健药物市场规模（按药物类型和复合年增长率） (2025-2032)

• 市场概况
• 阿克顿埃尔
• YAZ Yasmine Yasminell
• 福泰奥
• 米纳斯汀 24 Fe
• 米雷那
• 努瓦环
• 正三烯丙基氯化铵
• 普利马林
• 普罗利亚
• 雷克拉斯特/阿克斯特
• 泽瓦
• Zometa
• 其他的

女性保健药物市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局

女性保健药物市场规模（按应用划分）及复合年增长率（2025-2032）

• 市场概况
• 荷尔蒙性不孕
• 避孕药
• 停经后骨质疏鬆症
• 子宫内膜异位症和子宫肌瘤
• 闭经
• 卵巢症候群（PCOS）

女性保健药物市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Hologic, Inc.（United States）
• Pfizer Inc.（United States）
• AbbVie Inc.（United States）
• Bayer AG（Germany）
• Johnson & Johnson（United States）
• Eli Lilly and Company（United States）
• Sanofi SA（France）
• Gedeon Richter Plc.（Hungary）
• Sumitomo Pharma Co., Ltd.（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novartis AG（Switzerland）
• Merck & Co., Inc.（United States）
• AstraZeneca plc（United Kingdom）
• Organon & Co.（United States）
• Amgen Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Mithra Pharmaceuticals（Belgium）
• Aspira Women's Health Inc.（United States）
• Evofem Biosciences, Inc.（United States）

结论和建议

Women's Health Therapeutics Market size was valued at USD 13.7 billion in 2023 and is poised to grow from USD 14.45 billion in 2024 to USD 22.18 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The global women's health therapeutics market is witnessing a shift in consumer preferences, with an increasing demand for healthier snack options, particularly fruit snacks. This segment has shown resilience and steady growth, driven by the perception of fruit snacks as convenient and healthier alternatives. As consumers become more health-conscious, there is a notable preference for snacks that are low in calories, free from artificial additives, and composed of real fruit ingredients. This health-focused trend is expected to influence the market further. In response, companies in the fruit snacks sector are investing in product innovation by launching organic, non-GMO, and clean-label options, while also exploring new flavors and packaging solutions to attract a wider audience.

Top-down and bottom-up approaches were used to estimate and validate the size of the Women's Health Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Women's Health Therapeutics Market Segments Analysis

Global Women's Health Therapeutics Market is segmented by Age, Drug, Distribution Channel, Application and region. Based on Age, the market is segmented into 50 Years & Above and Others. Based on Drug, the market is segmented into ACTONEL, YAZ, Yasmin, Yasminelle, FORTEO, Minastrin 24 Fe, Mirena, NuvaRing, ORTHO TRI-CY LO, Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Application, the market is segmented into Hormonal Infertility,contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause and Polycystic Ovary Syndrome (PCOS). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Women's Health Therapeutics Market

The growing awareness and advocacy surrounding women's health issues have significantly boosted the demand for advanced therapeutic solutions tailored to conditions like menopause, reproductive disorders, and hormonal imbalances. This heightened interest is driving the market for women's health therapeutics, as consumers seek more effective treatments. Moreover, technological advancements in healthcare, such as precision medicine and the development of innovative drug formulations, are further accelerating therapeutic innovation in this sector. These factors collectively contribute to a dynamic market environment that prioritizes improved health outcomes for women, ensuring a continuous evolution in the therapeutic landscape designed specifically for female patients.

Restraints in the Women's Health Therapeutics Market

A significant constraint in the Women's Health Therapeutics market is the intricate regulatory landscape, characterized by rigorous approval processes that can delay product launches. This complexity often arises from concerns about potential side effects and safety risks linked to various therapeutic options, which can affect both regulatory evaluations and patient acceptance. Furthermore, persistent gender disparities in clinical research and access to healthcare services hinder the development of inclusive and effective therapeutic solutions for women's health. These factors together create substantial barriers, impacting the overall progress of innovation and availability in this essential market sector.

Market Trends of the Women's Health Therapeutics Market

The Women's Health Therapeutics market is experiencing a notable trend towards personalized medicine, emphasizing customized therapeutic approaches that consider genetic, hormonal, and lifestyle factors unique to women. This shift is fostering innovation in contraception, particularly with advancements in long-acting reversible contraceptives (LARCs) and the emergence of non-hormonal options. Furthermore, there is an increasing focus on developing novel therapies to address specific health issues such as endometriosis and polycystic ovary syndrome (PCOS). This holistic and tailored approach not only enhances treatment effectiveness but also empowers women to take charge of their health, marking a pivotal shift in the market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Women's Health Therapeutics Market Size by Age & CAGR (2025-2032)

• Market Overview
• 50 Years & Above
• Others

Global Women's Health Therapeutics Market Size by Drug & CAGR (2025-2032)

• Market Overview
• ACTONEL
• YAZ, Yasmin, Yasminelle
• FORTEO
• Minastrin 24 Fe
• Mirena
• NuvaRing
• ORTHO TRI-CY LO
• Premarin
• Prolia
• Reclast/Aclasta
• XGEVA
• Zometa
• Others

Global Women's Health Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Women's Health Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Hormonal Infertility
• Contraceptives
• Postmenopausal Osteoporosis
• Endometriosis & Uterine Fibroids
• Menopause
• Polycystic Ovary Syndrome (PCOS)

Global Women's Health Therapeutics Market Size & CAGR (2025-2032)

• North America (Age, Drug, Distribution Channel, Application)
  • US
  • Canada
• Europe (Age, Drug, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Age, Drug, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Age, Drug, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Age, Drug, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hologic, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc. (Hungary)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aspira Women's Health Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations